Survival of patients with KRAS wild-type metastatic colorectal cancer is identical after sequential treatment with cetuximab and bevacizumab regardless of the sequence – A retrospective single-center study

Objective: To investigate the overall survival of patients with KRAS wild-type metastatic colorectal cancer (mCRC) after sequentially receiving both bevacizumab and cetuximab during the course of treatment. Methods: Twenty-six mCRC patients who received both bevacizumab and cetuximab at the Sun Yat-...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Yanhong, Cai, Yue, Lin, Jiayu, Jiang, Ling, Hu, Huabin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650979/
https://www.ncbi.nlm.nih.gov/pubmed/26468218
http://dx.doi.org/10.1093/gastro/gov051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650979/
https://www.ncbi.nlm.nih.gov/pubmed/26468218
http://dx.doi.org/10.1093/gastro/gov051

Ejemplares similares